- Warning letters now target compounders as shortages close and patent cover runs to the 2030s
- Enforcement includes the TruHeight listing and a $150,000 NextMed refund order
- Readers can check approval, salt type, added vitamins and measured dose before use
Your bathroom shelf stays safer when a prescription copy is checked first, because shortages that once allowed compounded GLP-1s have closed and regulators started sending warning letters. Stanford Medicine reports that shift, with the FDA acting after shortages that began in 2022, while patents keep generic semaglutide away until at least 2032 and tirzepatide patents hold until 2036. As you track what goes on your body, the FTC lists a health claims case called TruHeight, In the Matter of, dated July 15, 2026.
GLP 1 stands for glucagon like peptide 1, a gut hormone tied to blood sugar and appetite control. Medicines that switch on its receptor mimic that signal. Semaglutide brands cover Ozempic, Wegovy and Rybelsus, and tirzepatide brands cover Mounjaro and Zepbound.
Copies made by compounders lack the FDA approval carried by brand-name medicines. In 2024 at the peak, almost 1 in 3 Americans using a GLP-1 drug reported supply through a compounding pharmacy. Patented GLP-1s list at more than $1,000 per month, and clinicians describe the cost and access pressures behind compounded use as genuine.
Recipes can vary in small but important details. Certain compounders use salt forms like semaglutide sodium, which FDA has not approved and which lack proof of safety and effectiveness in people. Many mix in vitamin B12 plus extras such as B6, niacinamide, glycine or carnitine without proven value for weight loss or diabetes care. A 2026 study showed tirzepatide mixed with B12 can join together, creating a molecule absent from the FDA-approved medicine, with Eli Lilly repeating the result.
Measurement adds further hazard. FDA has pointed to episodes where people using multidose vials took 10 to 20 times the prescribed quantity in error. Some compounding pharmacies offer semaglutide or tirzepatide as sublingual drops or dissolving tablets that clinical trials never assessed. Calls to poison control centers around the U.S. tied to injected weight-loss drugs grew by more than 15-fold since 2019.
The FTC issued a final order against telehealth company NextMed and principals Robert Epstein and Frank Leonardo involving GLP 1 weight loss programs. Its July 2025 complaint said NextMed marketed weight-loss programs with hidden costs, unsupported weight-loss promises, false testimonials and skewed reviews. The final order directs $150,000 in payment, intended for consumer refunds, and demands competent and reliable evidence behind claims about average or typical outcomes.
Marina Basina, MD, clinical professor in endocrinology, gerontology and metabolism, said using compounded drugs with GLP 1s and no medical supervision poses significant risk and can bring significant consequences.
Ellen Sloane
Ellen looks after the brands Body of Work works with and makes sure every sponsored page says so. She spent years in salon education for a professional hair care company, so she can tell a demonstration from a claim.
More from Ellen Sloane →
